Mazdutide

Mazdutide is an oxyntomodulin-related peptide activating both GLP-1 and glucagon receptors. Innovent Biologics develops the Chinese product under license from Eli Lilly, while the cited US study is Lilly-sponsored. It is injected weekly and is researched for weight and glycemic outcomes.

GLP-1 activity supports glucose-dependent insulin secretion, slower gastric emptying and reduced appetite. Glucagon-receptor activity is intended to increase energy expenditure and reduce liver fat. This second receptor differs from tirzepatide’s GIP target and from semaglutide’s selective GLP-1 action. Receptor count does not establish comparative efficacy, tolerability or each receptor’s contribution in a patient.

Mazdutide has no US FDA approval. China’s NMPA approved chronic weight management in 2025; the retrieved 信尔美 label records June 24, 2025. Type 2 diabetes approval followed in September 2025. Those decisions do not establish US availability, an FDA label or approval of every newer research dose.

GLORY-1 randomized 610 Chinese adults with obesity or overweight and comorbidities to weekly 4 mg, 6 mg or placebo over 48 weeks. Treatment-policy weight changes at the primary 32-week assessment were −10.09%, −12.55% and +0.45%, respectively; at 48 weeks they were −11.00%, −14.01% and +0.30%.

GLORY-2 studied 9 mg in Chinese adults with moderate-to-severe obesity: 462 were randomized and 461 treated. At 60 weeks, reported weight change was −16.65% versus −1.50% placebo, broadly about −17% versus −2%. A systematic review found consistent results in predominantly Chinese populations. Replicated positive Phase 3 outcomes support the Chinese approval but are not FDA approval.

A separate US Phase 2 study randomized 179 adults without type 2 diabetes. At the 32-week primary assessment, efficacy-estimand weight changes were −7.3%, −15.6% and −18.1% in the 3–6, 10 and 16 mg groups versus −0.9% placebo. The 3–6 mg group remained at 3 mg until week 32. These exposures and analyses differ from GLORY-1 and the Chinese label.

Positive weight or biomarker findings do not by themselves establish fewer cardiovascular events, better muscle preservation or superiority to semaglutide, tirzepatide or retatrutide. No matched head-to-head comparison is supplied; indirect comparisons and different ethnic/population characteristics require caution.

The retrieved Chinese weight-management label begins at 2 mg weekly, increases to 4 mg after four weeks and permits 6 mg after at least another four weeks when needed; maintenance is 4 or 6 mg. GLORY-2’s 9 mg and the higher US trial doses are separate research exposures, not a generic 8–10 mg prescription.

In GLORY-2, vomiting occurred in 53.1% versus 1.3% placebo, nausea in 46.9% versus 3.2% and diarrhea in 39.4% versus 6.5%; most events were mild or moderate. Adverse-event discontinuation was 2.9% versus 0%. In the US Phase 2 16 mg group it was 20%, mainly GI-related. A 2024 randomized-trial meta-analysis likewise found increased transient mild/moderate GI effects. The Chinese label includes thyroid C-cell warnings and MTC/MEN2 contraindications; absence of a GIP target does not guarantee better tolerability.